PRAXIS PRECISION MEDICINES I (PRAX) Fundamental Analysis & Valuation

NASDAQ:PRAX • US74006W2070

Current stock price

300.2 USD
+1.89 (+0.63%)
Last:

This PRAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PRAX Profitability Analysis

1.1 Basic Checks

  • PRAX had negative earnings in the past year.
  • In the past year PRAX has reported a negative cash flow from operations.
  • In the past 5 years PRAX always reported negative net income.
  • In the past 5 years PRAX always reported negative operating cash flow.
PRAX Yearly Net Income VS EBIT VS OCF VS FCFPRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • PRAX has a Return On Assets of -32.33%. This is in the better half of the industry: PRAX outperforms 63.20% of its industry peers.
  • The Return On Equity of PRAX (-34.54%) is better than 71.87% of its industry peers.
Industry RankSector Rank
ROA -32.33%
ROE -34.54%
ROIC N/A
ROA(3y)-70.12%
ROA(5y)-90.67%
ROE(3y)-84.17%
ROE(5y)-120.08%
ROIC(3y)N/A
ROIC(5y)N/A
PRAX Yearly ROA, ROE, ROICPRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200 -250

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRAX Yearly Profit, Operating, Gross MarginsPRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. PRAX Health Analysis

2.1 Basic Checks

  • PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRAX has been increased compared to 1 year ago.
  • PRAX has less shares outstanding than it did 5 years ago.
  • PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PRAX Yearly Shares OutstandingPRAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
PRAX Yearly Total Debt VS Total AssetsPRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • PRAX has an Altman-Z score of 81.25. This indicates that PRAX is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of PRAX (81.25) is better than 97.69% of its industry peers.
  • There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 81.25
ROIC/WACCN/A
WACC9.28%
PRAX Yearly LT Debt VS Equity VS FCFPRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • PRAX has a Current Ratio of 10.22. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 10.22, PRAX belongs to the best of the industry, outperforming 80.73% of the companies in the same industry.
  • A Quick Ratio of 10.22 indicates that PRAX has no problem at all paying its short term obligations.
  • PRAX has a Quick ratio of 10.22. This is amongst the best in the industry. PRAX outperforms 80.73% of its industry peers.
Industry RankSector Rank
Current Ratio 10.22
Quick Ratio 10.22
PRAX Yearly Current Assets VS Current LiabilitesPRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. PRAX Growth Analysis

3.1 Past

  • The earnings per share for PRAX have decreased strongly by -31.06% in the last year.
  • Looking at the last year, PRAX shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-31.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 48.56% on average over the next years. This is a very strong growth
  • PRAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 871.35% yearly.
EPS Next Y-14.22%
EPS Next 2Y8.14%
EPS Next 3Y33.17%
EPS Next 5Y48.56%
Revenue Next Year11208.8%
Revenue Next 2Y8470.93%
Revenue Next 3Y2876.58%
Revenue Next 5Y871.35%

3.3 Evolution

PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

1

4. PRAX Valuation Analysis

4.1 Price/Earnings Ratio

  • PRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRAX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRAX Price Earnings VS Forward Price EarningsPRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRAX Per share dataPRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PRAX's earnings are expected to grow with 33.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.14%
EPS Next 3Y33.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRAX Dividend Analysis

5.1 Amount

  • No dividends for PRAX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRAX Fundamentals: All Metrics, Ratios and Statistics

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (3/23/2026, 12:08:41 PM)

300.2

+1.89 (+0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-30
Inst Owners99.68%
Inst Owner Change15.47%
Ins Owners0.45%
Ins Owner Change1.82%
Market Cap8.36B
Revenue(TTM)N/A
Net Income(TTM)-303.27M
Analysts82.61
Price Target619.14 (106.24%)
Short Float %14.77%
Short Ratio7.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.19%
Min EPS beat(2)-10.67%
Max EPS beat(2)4.3%
EPS beat(4)2
Avg EPS beat(4)-1.14%
Min EPS beat(4)-10.67%
Max EPS beat(4)4.3%
EPS beat(8)3
Avg EPS beat(8)-6.09%
EPS beat(12)7
Avg EPS beat(12)3.96%
EPS beat(16)8
Avg EPS beat(16)1.22%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)175.71%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.54%
PT rev (3m)50.82%
EPS NQ rev (1m)-9.24%
EPS NQ rev (3m)-7.37%
EPS NY rev (1m)-14.91%
EPS NY rev (3m)-15.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-64.39%
Revenue NY rev (3m)-22.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.52
P/tB 9.52
EV/EBITDA N/A
EPS(TTM)-13.46
EYN/A
EPS(NY)-15.37
Fwd EYN/A
FCF(TTM)-8.95
FCFYN/A
OCF(TTM)-8.94
OCFYN/A
SpS0
BVpS31.53
TBVpS31.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.33%
ROE -34.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.12%
ROA(5y)-90.67%
ROE(3y)-84.17%
ROE(5y)-120.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.22
Quick Ratio 10.22
Altman-Z 81.25
F-Score3
WACC9.28%
ROIC/WACCN/A
Cap/Depr(3y)17.19%
Cap/Depr(5y)147.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
EPS Next Y-14.22%
EPS Next 2Y8.14%
EPS Next 3Y33.17%
EPS Next 5Y48.56%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year11208.8%
Revenue Next 2Y8470.93%
Revenue Next 3Y2876.58%
Revenue Next 5Y871.35%
EBIT growth 1Y-62.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.93%
EBIT Next 3Y18.2%
EBIT Next 5Y35.88%
FCF growth 1Y-89.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.04%
OCF growth 3YN/A
OCF growth 5YN/A

PRAXIS PRECISION MEDICINES I / PRAX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PRAXIS PRECISION MEDICINES I (PRAX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to PRAX.


What is the valuation status of PRAXIS PRECISION MEDICINES I (PRAX) stock?

ChartMill assigns a valuation rating of 1 / 10 to PRAXIS PRECISION MEDICINES I (PRAX). This can be considered as Overvalued.


What is the profitability of PRAX stock?

PRAXIS PRECISION MEDICINES I (PRAX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for PRAX stock?

The Earnings per Share (EPS) of PRAXIS PRECISION MEDICINES I (PRAX) is expected to decline by -14.22% in the next year.